Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Calmels

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Hematology/Oncology and Stem Cell Therapy|April 5, 2011
Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myelomaJean El Cheikh, Elias Kfoury, Boris Calmels, et al.
Bone Marrow Transplantation|September 20, 2019
Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantationCharlotte Nykolyszyn, Angela Granata, Thomas Pagliardini, et al.
American Journal of Hematology|March 6, 2013
Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myelomaJean El-Cheikh, Roberto Crocchiolo, Sabine Furst, et al.
Bone Marrow Transplantation|November 8, 2018
Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patientsThomas Pagliardini, Samia Harbi, Sabine Fürst, et al.
Bone Marrow Transplantation|March 15, 2024
Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell diseaseSabine Fürst, Emmanuelle Bernit, Faezeh Legrand, et al.
Experimental Hematology|March 27, 2012
Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myelomaJean El-Cheikh, Roberto Crocchiolo, Sabine Furst, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 6, 2010
Impact of viable CD45 cells infused on lymphocyte subset recovery after unrelated cord blood transplantation in childrenVincent Barlogis, Laurence Glasman, Corine Brunet, et al.
Clinical Epigenetics|October 14, 2019
Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutationSylvain Garciaz, Lia N'guyen Dasi, Pascal Finetti, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 17, 2014
Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantationRaynier Devillier, Samia Harbi, Sabine Fürst, et al.
Experimental Hematology|September 21, 2010
Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignanciesDidier Blaise, Laure Farnault, Catherine Faucher, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Hematology/Oncology and Stem Cell Therapy|April 5, 2011
Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myelomaJean El Cheikh, Elias Kfoury, Boris Calmels, et al.
Bone Marrow Transplantation|September 20, 2019
Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantationCharlotte Nykolyszyn, Angela Granata, Thomas Pagliardini, et al.
American Journal of Hematology|March 6, 2013
Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myelomaJean El-Cheikh, Roberto Crocchiolo, Sabine Furst, et al.
Bone Marrow Transplantation|November 8, 2018
Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patientsThomas Pagliardini, Samia Harbi, Sabine Fürst, et al.
Bone Marrow Transplantation|March 15, 2024
Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell diseaseSabine Fürst, Emmanuelle Bernit, Faezeh Legrand, et al.
Experimental Hematology|March 27, 2012
Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myelomaJean El-Cheikh, Roberto Crocchiolo, Sabine Furst, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 6, 2010
Impact of viable CD45 cells infused on lymphocyte subset recovery after unrelated cord blood transplantation in childrenVincent Barlogis, Laurence Glasman, Corine Brunet, et al.
Clinical Epigenetics|October 14, 2019
Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutationSylvain Garciaz, Lia N'guyen Dasi, Pascal Finetti, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 17, 2014
Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantationRaynier Devillier, Samia Harbi, Sabine Fürst, et al.
Experimental Hematology|September 21, 2010
Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignanciesDidier Blaise, Laure Farnault, Catherine Faucher, et al.
Pageof 7